Figure 4.

Evolution of immune cell subsets between D0 and D7, defines high-risk clinical grade COVID-19 patients

(A) Two first dimensions of correspondence analysis accounting for 94.1% of the association between immune clusters differentially expressed between groups (n = 4 monocyte and n = 22 lymphoid clusters) and patients for which a follow-up of 7 days was available (COVID-19⁻ARDS⁺ [n = 7], COVID-19⁺ARDS⁺ [n = 8], and COVID-19⁺ARDS⁻ [n = 6]). For clarity, patients and immune cells are shown on 2 different plots. Dimensions 1 and 2 coordinates were compared between D0 and D7 for each group of patients. Wilcoxon matched-pairs signed rank tests, ∗∗p < 0.01.

(B) Spearman correlation between immune and clinical score for COVID-19⁺ patients (ARDS⁺ [n = 8] and ARDS– [n = 6]).